Pharmaceutical Journal - Latest researchhttps://www.pharmaceutical-journal.com
https://www.pharmaceutical-journal.comhttps://www.pharmaceutical-journal.com/magazine/graphics/logo.png
https://www.pharmaceutical-journal.com
Optimising the health and wellbeing of older people living with HIV in the United Kingdom https://www.pharmaceutical-journal.com/research/review-article/optimising-the-health-and-wellbeing-of-older-people-living-with-hiv-in-the-united-kingdom/20204279.article
https://www.pharmaceutical-journal.com/research/review-article/optimising-the-health-and-wellbeing-of-older-people-living-with-hiv-in-the-united-kingdom/20204279.articleCare for people with HIV has improved, meaning that more people are living with HIV into older age with normal life expectancy. Therefore, there are various challenges and opportunities facing healthcare professionals when providing care to this changing demographic.Wed, 7 Feb 2018 14:44 GMTNHS Grampian project: treating uncomplicated lower urinary tract infection in community pharmacyhttps://www.pharmaceutical-journal.com/research/research-article/nhs-grampian-project-treating-uncomplicated-lower-urinary-tract-infection-in-community-pharmacy/20204055.article
https://www.pharmaceutical-journal.com/research/research-article/nhs-grampian-project-treating-uncomplicated-lower-urinary-tract-infection-in-community-pharmacy/20204055.articleUrinary tract infections (UTIs) are one of the most common conditions seen in female patients in general practice (GP) and account for 1–3% of all GP consultations each year in the UK. Over-the-counter (OTC) treatments for UTIs currently available in community pharmacy only attempt to relieve symptoms, and do not address the bacterial infection. The Grampian project was developed to provide treatment of uncomplicated UTIs through community pharmacies by means of a Patient Group Direction ...Tue, 9 Jan 2018 15:20 GMTTreatments for neuropathic painhttps://www.pharmaceutical-journal.com/research/review-article/treatments-for-neuropathic-pain/20203641.article
https://www.pharmaceutical-journal.com/research/review-article/treatments-for-neuropathic-pain/20203641.articleAbstract: Neuropathic pain (NP) is a common condition characterised by subjective negative and positive symptoms that range from numbness to debilitating pain. NP can have a significant negative impact on a patient’s quality of life. Pharmacotherapy is typically the first step in treating NP. Guidelines and consensus statements from various organisations around the world appear to be consistent with the classes of medications recommended for both general and specific types of NP, which ...Fri, 1 Dec 2017 00:00 GMTThe implications of the Montgomery judgment on pharmacy practice and patients with learning disabilityhttps://www.pharmaceutical-journal.com/research/perspective-article/the-implications-of-the-montgomery-judgment-on-pharmacy-practice-and-patients-with-learning-disability/20203788.article
https://www.pharmaceutical-journal.com/research/perspective-article/the-implications-of-the-montgomery-judgment-on-pharmacy-practice-and-patients-with-learning-disability/20203788.articleAbstract
Tue, 28 Nov 2017 15:03 GMTPharmacological treatment options for fibromyalgiahttps://www.pharmaceutical-journal.com/research/review-article/pharmacological-treatment-options-for-fibromyalgia/20203533.article
https://www.pharmaceutical-journal.com/research/review-article/pharmacological-treatment-options-for-fibromyalgia/20203533.articleFibromyalgia is a high-impact and prevalent condition. Its clinical features include widespread pain and tenderness — often associated with high levels of poor-quality sleep, fatigue and cognitive dysfunction. The mechanism leading to fibromyalgia development is associated with a change in the sensitivity of the pain-related nervous system, as well as other sensory systems. In turn, emotional distress plays a facilitatory role in this process. Non-pharmacological management focuses ...Tue, 7 Nov 2017 10:26 GMTPharmacologic treatment options for children and adolescents with autism spectrum disorderhttps://www.pharmaceutical-journal.com/research/review-article/pharmacologic-treatment-options-for-children-and-adolescents-with-autism-spectrum-disorder/20203390.article
https://www.pharmaceutical-journal.com/research/review-article/pharmacologic-treatment-options-for-children-and-adolescents-with-autism-spectrum-disorder/20203390.articleAutism spectrum disorder (ASD) is a heterogeneous neuropsychiatric condition that is often associated with severe behavioural challenges that can be as diverse in response to treatment as they are in presentation. While environmental, behavioural, communicative, therapeutic and supportive interventions are critical considerations for any individual with ASD, pharmacologic interventions are often helpful and can be necessary for improving level of functioning and quality ...Tue, 10 Oct 2017 15:43 GMTAntimicrobial therapies for Gram-positive infectionshttps://www.pharmaceutical-journal.com/research/antimicrobial-therapies-for-gram-positive-infections/20203363.article
https://www.pharmaceutical-journal.com/research/antimicrobial-therapies-for-gram-positive-infections/20203363.article Gram-positive bacteria are among the most common human pathogens associated with clinical infections, which range from mild skin infections to sepsis. In an era defined by antimicrobial resistance (AMR) and an increasing drive toward delivering patient care via ambulatory pathways, the paradigm for the management of infections is changing. Methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE), the best known cases of ...Tue, 12 Sep 2017 15:28 GMTAn update on the management of chronic hepatitis B and C infectionhttps://www.pharmaceutical-journal.com/research/an-update-on-the-management-of-chronic-hepatitis-b-and-c-infection/20203306.article
https://www.pharmaceutical-journal.com/research/an-update-on-the-management-of-chronic-hepatitis-b-and-c-infection/20203306.article Chronic hepatitis B and C infection are leading causes of liver-related morbidity and mortality worldwide. Current therapies for chronic hepatitis B virus (HBV) infection consisting of nucleos(t)ide analogues (NA) rarely lead to functional cure. With a better understanding of the HBV lifecycle, novel agents have been developed with the hope of achieving functional cure. The development of direct-acting antivirals (DAAs) for hepatitis C virus (HCV) therapy has led to ...Wed, 9 Aug 2017 14:46 GMTSafe dispensing in community pharmacies: applying the software, hardware, environment and liveware (SHELL) modelhttps://www.pharmaceutical-journal.com/research/safe-dispensing-in-community-pharmacies-applying-the-software-hardware-environment-and-liveware-shell-model/20202919.article
https://www.pharmaceutical-journal.com/research/safe-dispensing-in-community-pharmacies-applying-the-software-hardware-environment-and-liveware-shell-model/20202919.article The human aspects of the community pharmacy work system are vulnerable to medication-related errors. Established models of human error can identify actual or potential hazards, and are important in our understanding of the interaction between human and system factors that influence performance. The software, hardware, environment and liveware (SHELL) model, a traditional human factors framework, is used in this article to classify potential sources of error in community ...Sat, 1 Jul 2017 00:00 GMTExamining the implications of analytical and remote monitoring in pharmacy practicehttps://www.pharmaceutical-journal.com/research/examining-the-implications-of-analytical-and-remote-monitoring-in-pharmacy-practice/20202516.article
https://www.pharmaceutical-journal.com/research/examining-the-implications-of-analytical-and-remote-monitoring-in-pharmacy-practice/20202516.article Remote patient monitoring (RPM) incorporates digital technology that collects health data from individuals in one location and electronically transmits secure data to healthcare providers in a different location for review and assessment. This allows healthcare professionals to make recommendations to optimise patient care without the patient having to be in the healthcare setting. With the implementation of RPM, pharmacists can use objective data obtained by remote ...Mon, 5 Jun 2017 17:14 GMTCeftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitorhttps://www.pharmaceutical-journal.com/research/ceftazidime-avibactam-a-novel-cephalosporin/-lactamase-inhibitor/20202413.article
https://www.pharmaceutical-journal.com/research/ceftazidime-avibactam-a-novel-cephalosporin/-lactamase-inhibitor/20202413.article Over the past decade, infections caused by multidrug-resistant Gram-negative organisms have increased. The limited availability in treatment options for these infections prompted both the UK to create a five-year antimicrobial resistance strategic plan to stimulate the development of new antibiotics, and the Infectious Diseases Society of America to call for ten new antimicrobial agents to be developed by 2020. Ceftazidime-avibactam is a combination of a third-generation ...Wed, 10 May 2017 14:40 GMT